Items where authors include "Hussain, S.A."

Article

Grande, E. orcid.org/0000-0002-0134-4732, Bellmunt, J., Hussain, S.A. orcid.org/0000-0003-1552-511X et al. (26 more authors) (2025) Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey. The Oncologist, 30 (10). oyaf333. ISSN 1083-7159

Szabados, B.E. orcid.org/0000-0002-8786-0032, Guerrero-Ramos, F. orcid.org/0000-0002-0767-3465, Grande, E. orcid.org/0000-0002-0134-4732 et al. (14 more authors) (2025) On the horizon: a global multidisciplinary perspective on delivering emerging therapies for patients with BCG-naïve high-risk NMIBC. Oncology and Therapy, 13. pp. 275-291. ISSN 2366-1070

Conroy, S. orcid.org/0000-0001-7167-4908, Jubber, I., Noon, A.P. et al. (11 more authors) (2025) Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial. BJU International, 135 (2). pp. 329-338. ISSN 1464-4096

Wheatley, D.A. orcid.org/0000-0002-1919-5114, Berardi, R. orcid.org/0000-0002-9529-2960, Climent Duran, M.A. orcid.org/0000-0001-7523-0212 et al. (17 more authors) (2024) First-line avelumab plus chemotherapy in patients with advanced solid tumors: results from the phase Ib/II JAVELIN chemotherapy medley study. Cancer Research Communications, 4 (6). pp. 1609-1619. ISSN 2767-9764

Jones, R.J. orcid.org/0000-0002-2904-6980, Crabb, S.J. orcid.org/0000-0003-3521-9064, Linch, M. et al. (7 more authors) (2024) Systemic anticancer therapy for urothelial carcinoma: UK oncologists’ perspective. British Journal of Cancer, 130 (6). pp. 897-907. ISSN 0007-0920

Smith, T.A.D., West, C.M.L. orcid.org/0000-0002-0839-3449, Joseph, N. et al. (15 more authors) (2024) A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial. eBioMedicine, 101. 105032. ISSN 2352-3964

Catto, J.W.F. orcid.org/0000-0003-2787-8828, Tran, B., Rouprêt, M. et al. (64 more authors) (2024) Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Annals of Oncology, 35 (1). pp. 98-106. ISSN 0923-7534

Jubber, I. orcid.org/0000-0002-4558-2521, Morhardt, D.R., Griffin, J. orcid.org/0000-0003-3969-7637 et al. (10 more authors) (2023) Analysis of the distal urinary tract in larval and adult zebrafish reveals homology to the human system. Disease Models & Mechanisms, 16 (7). dmm050110. ISSN 1754-8403

Catto, J.W.F. orcid.org/0000-0003-2787-8828, Mandrik, O. orcid.org/0000-0003-3755-3031, Quayle, L.A. et al. (12 more authors) (2023) Diagnosis, treatment and survival from bladder, upper urinary tract and urethral cancers: real-world findings from NHS England between 2013 and 2019. BJU International, 131 (6). pp. 734-744. ISSN 1464-4096

Conroy, S., Pang, K., Jubber, I. et al. (5 more authors) (2023) Hyperthermic intravesical chemotherapy with mitomycin‐C for the treatment of high‐risk non‐muscle‐invasive bladder cancer patients. BJUI Compass, 4 (3). pp. 314-321. ISSN 2688-4526

James, N.D., Liu, W., Pirrie, S. orcid.org/0000-0002-2894-2230 et al. (9 more authors) (2022) TUXEDO: a phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer. BJU International, 131 (1). pp. 63-72. ISSN 1464-4096

Shimizu, N., Hussain, S.A. orcid.org/0000-0003-1552-511X, Obara, W. et al. (7 more authors) (2022) A phase 2 study of S-588410 maintenance monotherapy for platinum-treated advanced or metastatic urothelial carcinoma. Bladder Cancer, 8 (2). pp. 179-192. ISSN 2352-3727

Conroy, S., Hubbard, R., Noon, A.P. et al. (4 more authors) (2022) Case of the month from the University of Sheffield, UK : expediting definitive treatment in patients with invasive bladder cancer : an MRI-guided pathway. BJU International, 129 (6). pp. 691-694. ISSN 1464-4096

Hussain, S.A. orcid.org/0000-0003-1552-511X, Lester, J.F., Jackson, R. et al. (17 more authors) (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE) : a double-blind, randomised, phase 2 trial. The Lancet Oncology, 23 (5). pp. 650-658. ISSN 1470-2045

van der Heijden, MS, Powles, T, Petrylak, D et al. (22 more authors) (2022) Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature Communications, 13. 1878. ISSN 2041-1723

Williams, S.T., El Badri, S. and Hussain, S.A. orcid.org/0000-0003-1552-511X (2021) Urological cancer patients receiving treatment during COVID-19 : a single-centre perspective. British Journal of Cancer, 124 (9). pp. 1513-1515. ISSN 0007-0920

Ürün, Y., Hussain, S.A. orcid.org/0000-0003-1552-511X, Bakouny, Z. et al. (13 more authors) (2020) Survey of the impact of COVID-19 on oncologists’ decision making in cancer. Jco Global Oncology, 6. pp. 1248-1257. ISSN 2687-8941

Elmetwali, T., Salman, A., Wei, W. et al. (3 more authors) (2020) CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation. Scientific Reports, 10 (1). 342.

Hussain, S.A. orcid.org/0000-0003-1552-511X, Palmer, D.H., Syn, W.K. et al. (11 more authors) (2017) Gene expression profiling in bladder cancer identifies potential therapeutic targets. International Journal of Oncology, 50 (4). pp. 1147-1159. ISSN 1019-6439

Al-Jameel, W., Gou, X., Forootan, S.S. et al. (7 more authors) (2017) Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5. OncoTargets and Therapy, 8 (19). pp. 31041-31056. ISSN 1178-6930

Hussain, S.A. orcid.org/0000-0003-1552-511X, Ansari, J., Huddart, R. et al. (10 more authors) (2017) VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. International Journal of Oncology, 50 (3). pp. 768-772. ISSN 1791-2423

Choudhury, A., West, C.M., Porta, N. et al. (7 more authors) (2017) The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). British Journal of Cancer, 116 (5). pp. 649-657. ISSN 0007-0920

Al Fayi, M.S., Gou, X., Forootan, S.S. et al. (6 more authors) (2016) The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance. Oncotarget, 7 (50). pp. 82783-82797. ISSN 1949-2553

Andronis, L., Goranitis, I., Pirrie, S. et al. (19 more authors) (2016) Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. ISSN 1464-4096

Ansari, J., Hussain, S.A. orcid.org/0000-0003-1552-511X, Ansari, A. et al. (1 more author) (2013) Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma. Biologics: Targets and Therapy, 7. pp. 39-46. ISSN 1177-5475

Conference or Workshop Item

Hussain, S.A., Oughton, J.B. orcid.org/0000-0002-2047-804X, Smith Whelan, R. et al. (11 more authors) (2025) A phase Ib window of opportunity study of atezolizumab administered intravesically or direct injection in patients undergoing radical cystectomy for bladder cancer: Results of the single dose cohorts. In: 2025 ASCO Genitourinary Cancers Symposium, 13-15 Feb 2025, San Francisco, CA.

Hussain, S.A., Oughton, J.B. orcid.org/0000-0002-2047-804X, Smith Whelan, R. et al. (9 more authors) (2024) INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy. In: 2024 ASCO Genitourinary Cancers Symposium, 25-27 Jan 2024, San Francisco, CA.

Proceedings Paper

James, N.D., van de Wiel, J., Hughes, A. et al. (11 more authors) (2025) Feasibility and safety results from RAD-IO: a multi-stage trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer. In: Journal of Clinical Oncology. 2025 ASCO Genitourinary Cancers Symposium, 13-15 Feb 2025, San Francisco CA, USA. , p. 778.

Crabb, S.J., Hussain, S.A., Oughton, J.B. et al. (15 more authors) (2024) Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO. In: Journal of Clinical Oncology. 2024 ASCO Annual Meeting, 31 May - 04 Jun 2024, Chicago, USA. American Society of Clinical Oncology .